The mission of the Cystic Fibrosis (CF) Therapeutics Development Network (TDN) is to facilitate the clinical study of new and existing therapies to cure and control cystic fibrosis. 
 
The Centers for Disease Control (CDC) notes the many significant, harmful effects of tobacco use, including disease, disability, and damage to nearly every organ of the body. The European Respiratory Society (ERS) and the American Thoracic Society (ATS) have publicly condemned the involvement of tobacco or nicotine delivery systems industries in developing pulmonary therapies, and therefore will not include clinical trials results from companies with such ties in their publications nor will accept any research for oral presentations at its conferences. 
 
Because involvement with tobacco entities contradicts our mission, the CF TDN and its members are aligned with the position of the ERS and ATS. The TDN cannot sanction a clinical trial for conduct within the Network that, in the TDN’s view, has tobacco industry associations.